

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND COMPOSITION OF BOARD COMMITTEES

The Board hereby announces the following changes of independent non-executive Directors and composition of the Board committees with effect from 28 May 2021 :-

1. Mr. Karsono Tirtamarta (Kwee Yoe Chiang) has tendered his resignation as an independent non-executive Director of the Company. Subsequent to his resignation, Mr. Kwee has ceased to be the chairman of remuneration committee, and member for each of the audit committee and the nomination committee of the Company; and
2. Mr. Zeng Jinsong has been appointed as an independent non-executive Director, the chairman of remuneration committee, and member for each of the audit committee and the nomination committee of the Company.

RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “Board”) of directors (the “Directors”) of Yestar Healthcare Holdings Company Limited (the “Company”) hereby announces that Mr. Karsono Tirtamarta (Kwee Yoe Chiang) (“Mr. Kwee”) has tendered his resignation as an independent non-executive Director of the Company with effect from 28 May 2021 due to his retirement upon his age of 74.

Mr. Kwee has confirmed to the Board that he has no disagreement with the Board and there is nothing relating to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange of Hong Kong Limited (the “Stock Exchange”).

The Board would like to take this opportunity to express its gratitude to Mr. Kwee as an executive Director for his contributions to the Company during his terms of service.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board further announces that Mr. Zeng Jinsong (“Mr. Zeng”) has been appointed as an independent non-executive Director of the Company with effect from 28 May 2021. The biographical details of Mr. Zeng is set out below:

Mr. Zeng, aged 61, has over 30 years of experience in project management as well as research and development. Since 2007, Mr. Zeng has been the vice president of CP Group and is primarily responsible for the research of digital agriculture and agricultural modernisation, the management of new agricultural projects, the cooperation between enterprises and universities, government relations and the cooperation of international industry projects. In addition, he is also the chairman of 正大能源有限公司 (Zhengda Energy Co. Ltd.) and is responsible for the review of the company’s operation plans.

Since 2013, Mr. Zeng has been appointed as the Secretary General of the Steering Committee under the China Institute of Rural Studies, Tsinghua University. Since 2016, Mr. Zeng has been appointed as the Secretary General of the Institute of Global Development, Tsinghua University (and the Deputy Director and Secretary General of 醫療與健康研究中心 (the Medical and Healthcare Research Centre) under the Institute of Global Development) and the Chief Consultant to the Center for Development of Sports Industry, Tsinghua University. Since 2019, Mr. Zeng has been appointed as the Deputy Director and Secretary General of 世界文化發展研究中心 (the Research Centre for World Cultural Development), Tsinghua University and the Secretary General of the Institute for Global Industry, Tsinghua University since 2020.

Mr. Zeng obtained a bachelor’s degree in mechanics from the Southeast University (formerly known as the Nanjing Institute of Technology) in 1982, a master’s degree in vehicle vibration from the Beijing Institute of Technology in 1984, and a doctoral degree in vehicle dynamics from Tsinghua University in 1988.

Mr. Zeng has signed a letter of appointment with the Company for a term of three years with effect from 28 May 2021 with an annual director’s fee of RMB204,000 which was determined with reference to his duties and responsibilities, the Company’s remuneration policy, the prevailing market conditions and recommendations of the remuneration committee of the Board. Mr. Zeng’s remuneration will be subject to annual review by the remuneration committee of the Board and the Board from time to time with reference to his responsibility and performance.

Mr. Zeng shall hold office until the next general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Save as disclosed in this announcement, Mr. Zeng does not hold any other positions in the Company or its subsidiaries nor any directorship in other listed public company in the last three years.

Mr. Zeng does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company.

Further, Mr. Zeng does not have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) (the “SFO”) of the Company as at the date of this announcement.

Save as disclosed above, there was no matter relating to the appointment of Mr. Zeng that needs to be brought to the attention of the shareholders and there is no other information which is required to be disclosed pursuant to any requirements of Rules 13.51(2) (h) to (v) of the Listing Rules.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Subsequent to the resignation of Mr. Kwee, Mr. Kwee has ceased to be the chairman of remuneration committee, and member for each of the audit committee and the nomination committee of the Company with effect from 28 May 2021. Mr. Zeng, an independent non-executive Director, has also been appointed as the chairman of remuneration committee, and member for each of the audit committee and the nomination committee of the Company.

The Board would also like to express its warmest welcome to Mr. Zeng on his appointment.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

28 May 2021

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Ms. Wang Hong and Ms. Liao Changxiang; the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.